Literature DB >> 31178244

The Complexity of PRC2 Subcomplexes.

Guido van Mierlo1, Gert Jan C Veenstra2, Michiel Vermeulen1, Hendrik Marks3.   

Abstract

Polycomb repressive complex 2 (PRC2) is a multisubunit protein complex essential for the development of multicellular organisms. Recruitment of PRC2 to target genes, followed by deposition and propagation of its catalytic product histone H3 lysine 27 trimethylation (H3K27me3), are key to the spatiotemporal control of developmental gene expression. Recent breakthrough studies have uncovered unexpected roles for substoichiometric PRC2 subunits in these processes. Here, we elaborate on how the facultative PRC2 subunits regulate catalytic activity, locus-specific PRC2 binding, and propagation of H3K27me3, and how this affects chromatin structure, gene expression, and cell fate.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  H3K27me3; Polycomb repressive complex 2 (PRC2); embryonic development; gene regulation; mouse embryonic stem cells (ESCs); protein complex composition

Mesh:

Substances:

Year:  2019        PMID: 31178244     DOI: 10.1016/j.tcb.2019.05.004

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  71 in total

1.  Competition between PRC2.1 and 2.2 subcomplexes regulates PRC2 chromatin occupancy in human stem cells.

Authors:  Daniel T Youmans; Anne R Gooding; Robin D Dowell; Thomas R Cech
Journal:  Mol Cell       Date:  2020-12-17       Impact factor: 17.970

2.  Chromatin Organization in Early Land Plants Reveals an Ancestral Association between H3K27me3, Transposons, and Constitutive Heterochromatin.

Authors:  Sean A Montgomery; Yasuhiro Tanizawa; Bence Galik; Nan Wang; Tasuku Ito; Takako Mochizuki; Svetlana Akimcheva; John L Bowman; Valérie Cognat; Laurence Maréchal-Drouard; Heinz Ekker; Syuan-Fei Hong; Takayuki Kohchi; Shih-Shun Lin; Li-Yu Daisy Liu; Yasukazu Nakamura; Lia R Valeeva; Eugene V Shakirov; Dorothy E Shippen; Wei-Lun Wei; Masaru Yagura; Shohei Yamaoka; Katsuyuki T Yamato; Chang Liu; Frédéric Berger
Journal:  Curr Biol       Date:  2020-01-30       Impact factor: 10.834

Review 3.  Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction.

Authors:  Yiran Guo; Shuai Zhao; Gang Greg Wang
Journal:  Trends Genet       Date:  2021-01-22       Impact factor: 11.639

Review 4.  Chromatin regulation and dynamics in stem cells.

Authors:  David C Klein; Sarah J Hainer
Journal:  Curr Top Dev Biol       Date:  2019-12-30       Impact factor: 4.897

Review 5.  EZH2-Targeted Therapies in Cancer: Hype or a Reality.

Authors:  Marie-Lisa Eich; James E Ferguson; Sooryanarayana Varambally; Mohammad Athar
Journal:  Cancer Res       Date:  2020-09-25       Impact factor: 12.701

6.  Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity.

Authors:  Sara A Miller; Manashree Damle; Jongmin Kim; Robert E Kingston
Journal:  Development       Date:  2021-04-15       Impact factor: 6.868

Review 7.  Epigenetic Mechanisms Involved in the Cardiovascular Toxicity of Anticancer Drugs.

Authors:  Panagiota Papazoglou; Luying Peng; Agapios Sachinidis
Journal:  Front Cardiovasc Med       Date:  2021-04-27

8.  EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.

Authors:  Suresh Bugide; Romi Gupta; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 11.205

Review 9.  The roles of Polycomb repressive complexes in mammalian development and cancer.

Authors:  Andrea Piunti; Ali Shilatifard
Journal:  Nat Rev Mol Cell Biol       Date:  2021-03-15       Impact factor: 94.444

10.  LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p.

Authors:  Jishui Zhang; Wenhao Lv; Yagang Liu; Weihua Fu; Baosheng Chen; Qiutong Ma; Xin Gao
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.